Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Other Operating Expenses (2016 - 2023)

Altimmune (ALT) has disclosed Other Operating Expenses for 9 consecutive years, with $12.4 million as the latest value for Q4 2023.

  • On a quarterly basis, Other Operating Expenses changed N/A to $12.4 million in Q4 2023 year-over-year; TTM through Sep 2024 was $12.4 million, a N/A change, with the full-year FY2023 number at $12.4 million, changed N/A from a year prior.
  • Other Operating Expenses was $12.4 million for Q4 2023 at Altimmune, up from $3.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $12.4 million in Q4 2023 to a low of $72.0 in Q3 2021.
  • A 3-year average of $5.0 million and a median of $3.3 million in 2021 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 102.54% in 2019; the steepest drop was 102.54% in 2019.
  • Altimmune's Other Operating Expenses stood at $999999.0 in 2019, then surged by 230.04% to $3.3 million in 2021, then surged by 276.29% to $12.4 million in 2023.
  • Per Business Quant, the three most recent readings for ALT's Other Operating Expenses are $12.4 million (Q4 2023), $3.3 million (Q4 2021), and $72.0 (Q3 2021).